Breaking News Instant updates and real-time market news.

REGN

Regeneron

$371.68

-4.11 (-1.09%)

, TEVA

Teva

$42.96

-1.32 (-2.98%)

07:03
10/17/16
10/17
07:03
10/17/16
07:03

Teva, Regeneron plan to design pivotol Phase 3 study in chronic low back pain

REGN

Regeneron

$371.68

-4.11 (-1.09%)

TEVA

Teva

$42.96

-1.32 (-2.98%)

  • 30

    Oct

  • 04

    Nov

  • 06

    Nov

  • 15

    Nov

  • 29

    Mar

REGN Regeneron
$371.68

-4.11 (-1.09%)

09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.
10/13/16
BTIG
10/13/16
NO CHANGE
Target $18
BTIG
Buy
Ocular deal with Regeneron has favorable terms, says BTIG
BTIG analyst Ling Wang believes Ocular Therapeutix's (OCUL) strategic collaboration with Regeneron (REGN) comes with favorable deal terms. The back-end loaded structure brings the potential for large upside, Wang tells investors in a research note. In addition, the partnership provides external validation for Ocular's platform technology, Wang adds. The analyst reiterates a Buy rating on the shares with an $18 price target
TEVA Teva
$42.96

-1.32 (-2.98%)

10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.
10/07/16
LEER
10/07/16
NO CHANGE
Target $57
LEER
Outperform
Teva price target lowered to $57 from $61 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
10/12/16
LEER
10/12/16
NO CHANGE
Target $70
LEER
Outperform
Neurocrine recent selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.

TODAY'S FREE FLY STORIES

ELLI

Ellie Mae

$110.72

1.55 (1.42%)

16:43
04/27/17
04/27
16:43
04/27/17
16:43
Earnings
Ellie Mae reports Q1 adjusted EPS 25c, consensus 21c »

Reports Q1 revenue $93M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

  • 10

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

FII

Federated Investors

$28.08

0.18 (0.65%)

16:43
04/27/17
04/27
16:43
04/27/17
16:43
Earnings
Federated Investors reports Q1 EPS 49c, consensus 46c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

HLS

HealthSouth

$43.50

0.03 (0.07%)

16:43
04/27/17
04/27
16:43
04/27/17
16:43
Earnings
HealthSouth reports Q1 adjusted EPS 70c, consensus 65c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 04

    May

LUV

Southwest

$55.75

-1.19 (-2.09%)

, AAL

American Airlines

$43.98

-2.42 (-5.22%)

16:43
04/27/17
04/27
16:43
04/27/17
16:43
General news
On The Fly: Top stock stories for Thursday »

Stocks began the session…

LUV

Southwest

$55.75

-1.19 (-2.09%)

AAL

American Airlines

$43.98

-2.42 (-5.22%)

UAL

United Continental

$70.70

-0.63 (-0.88%)

CMCSA

Comcast

$39.59

0.8 (2.06%)

CMCSK

Comcast

UPS

UPS

$108.83

1.21 (1.12%)

PYPL

PayPal

$47.15

2.74 (6.17%)

UAA

Under Armour

$21.67

1.96 (9.94%)

F

Ford

$11.47

-0.13 (-1.12%)

DOW

Dow Chemical

$63.19

-1.14 (-1.77%)

SNCR

Synchronoss

$13.29

-11.33 (-46.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 04

    May

  • 04

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 16

    May

  • 17

    May

  • 18

    May

  • 19

    May

  • 31

    May

  • 31

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

IVC

Invacare

$13.25

0.2 (1.53%)

16:42
04/27/17
04/27
16:42
04/27/17
16:42
Hot Stocks
Invacare reports completion of consent decree milestones »

Invacare reported it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 18

    May

VCRA

Vocera

$24.96

0.42 (1.71%)

16:41
04/27/17
04/27
16:41
04/27/17
16:41
Earnings
Vocera sees Q2 adjusted EPS (8c)-(3c), consensus 2c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 17

    May

  • 30

    May

BNFT

Benefitfocus

$30.85

0.9 (3.01%)

16:41
04/27/17
04/27
16:41
04/27/17
16:41
Earnings
Benefitfocus sees FY17 EPS (37c)-(24c), consensus (31c) »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

VCRA

Vocera

$24.96

0.42 (1.71%)

16:41
04/27/17
04/27
16:41
04/27/17
16:41
Earnings
Vocera cuts FY17 adjusted EPS view to 2c-19c from 7c-24c, consensus 19c »

Backs FY17 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 17

    May

  • 30

    May

SSNC

SS&C

$37.65

0.34 (0.91%)

16:41
04/27/17
04/27
16:41
04/27/17
16:41
Earnings
SS&C sees FY17 adjusted revenue $1.66B-$1.69B, consensus $1.67B »

Reports FY17 adjusted net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

VCRA

Vocera

$24.96

0.42 (1.71%)

16:40
04/27/17
04/27
16:40
04/27/17
16:40
Earnings
Vocera reports Q1 adjusted EPS (5c), consensus (8c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 17

    May

  • 30

    May

BNFT

Benefitfocus

$30.85

0.9 (3.01%)

16:40
04/27/17
04/27
16:40
04/27/17
16:40
Earnings
Benefitfocus sees Q2 EPS (16c)-(13c), consensus (13c) »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

IRET

Investors Real Estate

$6.07

-0.09 (-1.46%)

16:40
04/27/17
04/27
16:40
04/27/17
16:40
Hot Stocks
Investors Real Estate announces CEO, senior management changes »

IRET, in a continuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNC

SS&C

$37.65

0.34 (0.91%)

16:39
04/27/17
04/27
16:39
04/27/17
16:39
Earnings
SS&C sees Q2 adjusted revenue $408M-$416M, consensus $412.69M »

Sees Q2 adjusted net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

MSTR

MicroStrategy

$192.49

-0.52 (-0.27%)

16:39
04/27/17
04/27
16:39
04/27/17
16:39
Earnings
MicroStrategy reports Q1 GAAP EPS $1.28, may not compare to consensus $1.47 »

Reports Q1 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

ECOL

US Ecology

$48.45

-0.25 (-0.51%)

16:39
04/27/17
04/27
16:39
04/27/17
16:39
Earnings
US Ecology backs FY17 EPS $1.69-$1.93, consensus $1.79 »

"Overall, business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

SSNC

SS&C

$37.65

0.34 (0.91%)

16:38
04/27/17
04/27
16:38
04/27/17
16:38
Earnings
SS&C reports Q1 adjusted EPS 44c, consensus 44c »

Reports Q1 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

INVA

Innoviva

$12.59

-0.26 (-2.02%)

16:38
04/27/17
04/27
16:38
04/27/17
16:38
Earnings
Innoviva reports Q1 adjusted EPS 19c, consensus 26c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

BNFT

Benefitfocus

$30.85

0.9 (3.01%)

16:38
04/27/17
04/27
16:38
04/27/17
16:38
Earnings
Benefitfocus reports Q1 EPS (11c), consensus (13c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

16:38
04/27/17
04/27
16:38
04/27/17
16:38
Earnings
Sarepta raises FY17 revenue from above $80M to above $95M, consensus $97.78M »

"Based on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOL

US Ecology

$48.45

-0.25 (-0.51%)

16:37
04/27/17
04/27
16:37
04/27/17
16:37
Earnings
US Ecology reports Q1 EPS 24c, consensus 30c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

GOOGL

Alphabet Class A

$891.44

2.3 (0.26%)

16:37
04/27/17
04/27
16:37
04/27/17
16:37
Hot Stocks
Alphabet Class A shares rise 5% to $935 after earnings beat »

Alphabet Class A shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIQUY

Air Liquide

$24.16

-0.23 (-0.94%)

, LECO

Lincoln Electric

$89.58

-0.71 (-0.79%)

16:37
04/27/17
04/27
16:37
04/27/17
16:37
Hot Stocks
Air Liquide to sell welding unit to Lincoln Electric France »

Air Liquide (AIQUY)…

AIQUY

Air Liquide

$24.16

-0.23 (-0.94%)

LECO

Lincoln Electric

$89.58

-0.71 (-0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

16:37
04/27/17
04/27
16:37
04/27/17
16:37
General news
Money Supply M2 Weekly Change data reported »

Week of 4/17 Money Supply…

16:36
04/27/17
04/27
16:36
04/27/17
16:36
General news
Fed Balance Sheet Level data reported »

Week of 4/26 Fed Balance…

RMD

ResMed

$72.85

1.1 (1.53%)

16:36
04/27/17
04/27
16:36
04/27/17
16:36
Earnings
ResMed reports Q3 non-GAAP EPS 71c, consensus 71c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 06

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.